MCID: ORP003
MIFTS: 54

Oropharynx Cancer

Categories: Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Oropharynx Cancer

MalaCards integrated aliases for Oropharynx Cancer:

Name: Oropharynx Cancer 12 15 17
Oropharyngeal Cancer 12 36 54 15
Malignant Neoplasm of Oropharynx 12 71 32
Oropharyngeal Carcinoma 12 71
Primary Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Neoplasm of Junctional Region of Oropharynx 12
Malignant Neoplasm of Posterior Wall of Oropharynx 12
Malignant Neoplasm of Lateral Wall of Oropharynx 12
Malignant Tumor of Posterior Wall of Oropharynx 12
Malignant Tumour of Mesopharynx 12
Malignant Oropharyngeal Tumor 12
Malignant Tumor of Oropharynx 12
Oropharyngeal Cancer, Adult 52
Cancer of the Oropharynx 52

Classifications:



External Ids:

Disease Ontology 12 DOID:8557
KEGG 36 H01559
NCIt 49 C7398
SNOMED-CT 67 93933005 93971002
UMLS 71 C0153382 C0153388 C0153389 more

Summaries for Oropharynx Cancer

KEGG : 36 Oropharyngeal cancer is a generic term that includes tumors arising within the anatomic confines of the posterior pharyngeal wall, soft palate, tonsillar region and posterior one-third (base) of the tongue. The vast majority of these tumors (>95%) includes squamous cell carcinomas of mucosal origin. Oropharyngeal squamous cell carcinomas (OPSCCs) are traditionally categorized as head and neck squamous cell carcinoma (HNSCC). High-risk human papillomavirus (HR-HPV) is now recognised as a causative agent in a subset of OPSCCs. HPV-driven OPSCC and tobacco- and alcohol-related OPSCC are biologically distinct entities. In the former, p53 and pRb are both inactivated at the protein level by, respectively, E6 and E7 viral oncoproteins. The majority of HPV-negative tumors, instead, harbor mutations in the TP53 gene, an increased epidermal growth factor receptor (EGFR) gene copy number and higher EGFR expression by immunohistochemistry (IHC).

MalaCards based summary : Oropharynx Cancer, also known as oropharyngeal cancer, is related to oral cancer and hypopharynx cancer. An important gene associated with Oropharynx Cancer is CDKN2A (Cyclin Dependent Kinase Inhibitor 2A), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Endometrial cancer. The drugs sodium fluoride and Nicotine have been mentioned in the context of this disorder. Affiliated tissues include the, tongue and lymph node, and related phenotypes are homeostasis/metabolism and endocrine/exocrine gland

Disease Ontology : 12 A pharynx cancer that is located in the oropharynx.

Wikipedia : 74 Oropharyngeal cancer (OPC) is a disease in which abnormal cells with the potential to both grow locally... more...

Related Diseases for Oropharynx Cancer

Diseases related to Oropharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 436)
# Related Disease Score Top Affiliating Genes
1 oral cancer 31.0 TP53 EGFR CDKN2A ADH1C
2 hypopharynx cancer 30.9 TP53 MMP8 EGFR CDKN2A
3 nasopharyngeal carcinoma 30.9 TP53 MIR9-1 ERBB2 EGFR CDKN2A
4 tongue cancer 30.9 TP53 MMP8 EGFR CDKN2A
5 anogenital venereal wart 30.8 TP53 H2AC18 GP5 CDKN2A
6 cervix uteri carcinoma in situ 30.8 TP53 GP5 CDKN2A
7 anus cancer 30.8 TP53 KIT H2AC18 GP5 EGFR CDKN2A
8 cervical cancer 30.7 TYMP TP53 MIR9-1 ERBB2 EGFR CDKN2A
9 tonsil squamous cell carcinoma 30.6 MIR193B CDKN2A
10 exanthem 30.6 KIT H2AC18 ERBB2 EGFR
11 tongue disease 30.5 TP53 MMP8 EGFR CDKN2A
12 esophagitis 30.5 TP53 EGFR CDKN2A
13 skin squamous cell carcinoma 30.5 TP53 KIT EGFR CDKN2A
14 small cell carcinoma 30.5 TP53 KIT EGFR CDKN2A
15 cervical squamous cell carcinoma 30.4 TYMP TP53 EGFR CDKN2A
16 squamous cell carcinoma, head and neck 30.3 TYMP TP53 MMP8 MIR9-1 H2AC18 ERBB2
17 in situ carcinoma 30.3 TP53 H2AC18 ERBB2 EGFR CDKN2A
18 ovarian disease 30.1 TP53 KIT H2AC18 ERBB2 EGFR CDKN2A
19 esophageal cancer 30.0 TYMP TP53 MIR9-1 ERBB2 EGFR CDKN2A
20 suppression of tumorigenicity 12 30.0 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
21 meningioma, familial 30.0 TP53 SERPINA3 KIT H2AC18 ERBB2 EGFR
22 leukemia, acute myeloid 29.9 TP53 SERPINA3 MIR9-1 KIT H2AC18 ERBB2
23 adenoid cystic carcinoma 29.7 TP53 SERPINA3 NFIB MYBL1 KIT ERBB2
24 pharynx cancer 29.7 TP53 SERPINA3 NFIB MMP8 MIR9-1 MIR193B
25 keratosis 29.6 TP53 EGFR CDKN2A
26 oral cavity cancer 29.6 TP53 SERPINA3 MMP8 MIR9-1 MIR193B MAML2
27 tonsil cancer 29.5 TP53 SERPINA3 NFIB MYBL1 MIR193B MAML2
28 lung cancer susceptibility 3 29.4 TYMP TP53 SERPINA3 MIR9-1 MIR193B KIT
29 obsolete: hiv-related oropharyngeal cancer 12.4
30 cutaneous telangiectasia and cancer syndrome, familial 12.2
31 vulvar intraepithelial neoplasia 10.7 TP53 CDKN2A
32 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
33 anus basaloid carcinoma 10.7 KIT CDKN2A
34 parotid gland adenoid cystic carcinoma 10.7 ERBB2 CDKN2A
35 cervical adenoid cystic carcinoma 10.7 NFIB KIT CDKN2A
36 acinar cell cystadenocarcinoma 10.7 SERPINA3 ACCS
37 trachea adenoid cystic carcinoma 10.7 KIT ACCS
38 ovarian seromucinous carcinoma 10.7 TP53 CDKN2A
39 supraglottis cancer 10.7 MMP8 EGFR CDKN2A
40 esophagus verrucous carcinoma 10.7 TP53 EGFR CDKN2A
41 verrucous carcinoma 10.7 TP53 EGFR CDKN2A
42 lacrimal system cancer 10.7 NFIB MAML2 ACCS
43 lacrimal gland mucoepidermoid carcinoma 10.7 MAML2 CRTC1
44 hyperplastic polyposis syndrome 10.7 TP53 APC
45 heart leiomyosarcoma 10.7 KIT CDKN2A
46 bone squamous cell carcinoma 10.6 TP53 EGFR CDKN2A
47 spitz nevus 10.6 TP53 CDKN2A
48 esophageal basaloid squamous cell carcinoma 10.6 TP53 EGFR
49 lacrimal gland adenocarcinoma 10.6 NFIB ACCS
50 fibrosarcoma of bone 10.6 SERPINA3 KIT CDKN2A

Comorbidity relations with Oropharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Oropharynx Cancer:



Diseases related to Oropharynx Cancer

Symptoms & Phenotypes for Oropharynx Cancer

MGI Mouse Phenotypes related to Oropharynx Cancer:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.97 ADH1C APC CDKN2A CRTC1 EGFR ERBB2
2 endocrine/exocrine gland MP:0005379 9.91 APC CDKN2A CRTC1 EGFR ERBB2 KIT
3 neoplasm MP:0002006 9.5 APC CDKN2A EGFR ERBB2 KIT MMP8
4 pigmentation MP:0001186 9.02 APC CDKN2A EGFR KIT TP53

Drugs & Therapeutics for Oropharynx Cancer

Drugs for Oropharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 sodium fluoride Approved Phase 4 7681-49-4
2
Nicotine Approved Phase 4 54-11-5 942 89594
3
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
4
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
5 Cariostatic Agents Phase 4
6 Listerine Phase 4
7 Psychotropic Drugs Phase 4
8 Central Nervous System Stimulants Phase 4
9 Cholinergic Agents Phase 4
10 Nicotinic Agonists Phase 4
11 Liver Extracts Phase 4
12 Dopamine Agents Phase 4
13 Cytochrome P-450 Enzyme Inhibitors Phase 4
14 Dopamine Uptake Inhibitors Phase 4
15 Antidepressive Agents Phase 4
16 Cytochrome P-450 CYP2D6 Inhibitors Phase 4
17 Mitomycins Phase 4
18
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
19
Ropivacaine Approved Phase 3 84057-95-4 71273 175805
20
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
21
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
22
nivolumab Approved Phase 3 946414-94-4
23
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
24
Durvalumab Approved, Investigational Phase 3 1428935-60-7
25
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
26
Cetuximab Approved Phase 3 205923-56-4 56842117 2333
27
Icodextrin Approved, Investigational Phase 3 337376-15-5
28 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
29
Lobeline Investigational Phase 2, Phase 3 90-69-7
30
Tremelimumab Investigational Phase 3 745013-59-6
31 Anticonvulsants Phase 3
32 Tranquilizing Agents Phase 3
33 Anti-Anxiety Agents Phase 3
34 Excitatory Amino Acid Antagonists Phase 3
35 Excitatory Amino Acids Phase 3
36 Antimanic Agents Phase 3
37 Respiratory System Agents Phase 2, Phase 3
38 Muscarinic Agonists Phase 2, Phase 3
39 Immunoglobulin G Phase 2, Phase 3
40 Pharmaceutical Solutions Phase 3
41
Amifostine Approved, Investigational Phase 2 20537-88-6 2141
42
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
43
Indinavir Approved Phase 2 150378-17-9 5362440
44
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
45
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
46
Trioxsalen Approved Phase 2 3902-71-4 5585
47
Valproic acid Approved, Investigational Phase 2 99-66-1 3121
48
Zinc Approved, Investigational Phase 2 7440-66-6 32051
49
Zinc oxide Approved Phase 2 1314-13-2
50
Ketorolac Approved Phase 2 66635-83-4, 74103-06-3 3826

Interventional clinical trials:

(show top 50) (show all 232)
# Name Status NCT ID Phase Drugs
1 Essential Oils With and Without Alcohol: in Vivo Antibacterial Effect Unknown status NCT03146390 Phase 4 Essential oils;Alcohol free essential oils
2 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
4 Comparative Effectiveness Trial of Transoral Head and Neck Surgery Followed by Adjuvant Radio(Chemo)Therapy Versus Primary Radiochemotherapy for Oropharyngeal Cancer Recruiting NCT03691441 Phase 4 Chemotherapy
5 Phase III Randomized Study of Radiotherapy With or Without Cisplatin and Fluorouracil for Locally Advanced, Nonresectable Squamous Cell Cancer of the Oropharynx or Hypopharynx Unknown status NCT00003627 Phase 3 cisplatin;fluorouracil
6 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
7 Effects of the Bilateral Mandibular Nerve Block (V3) in Mandibular Osteotomy: a Prospective, Randomized, Double-blind Versus Placebo Study Unknown status NCT02618993 Phase 3
8 Randomized Phase III, Double-Blind, Placebo Controlled Study of Prophylactic Gabapentin for the Reduction of Radiation Therapy Induced Pain During the Treatment of Oropharyngeal Squamous Cell Carcinoma Unknown status NCT03269344 Phase 3 Gabapentin;Placebo Oral Capsule
9 Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection (ESSAN): a Double-blinded, Randomized Control Trial Unknown status NCT02268344 Phase 3
10 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Unknown status NCT00964977 Phase 3
11 A Phase III Study to Test the Efficacy and Safety of GM-CSF to Reduce the Severity and Duration of Mucosal Injury and Pain (Mucositis) Associated With Curative Radiation Therapy in Head and Neck Cancer Patients Completed NCT00008398 Phase 3
12 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
13 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
14 A Pilot Study to Compare the Nicotine Lozenge and Tobacco-Free Snuff for Smokeless Tobacco Reduction Completed NCT01018394 Phase 2, Phase 3 nicotine lozenges;tobacco-free snuff
15 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
16 DART-HPV: A Phase III Evaluation of De-escalated Adjuvant Radiation Therapy for HPV-Associated Oropharynx Cancer Recruiting NCT02908477 Phase 3 Docetaxel;Cisplatin
17 A Phase II/III Randomized Study of Maintenance Nivolumab Versus Observation in Patients With Locally Advanced, Intermediate Risk HPV Positive OPCA Recruiting NCT03811015 Phase 2, Phase 3 Cisplatin
18 Phase III Randomised Controlled Trial Comparing Alternative Regimens for Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer Recruiting NCT04116047 Phase 3 Cisplatin;Durvalumab
19 Patient Reported Outcomes in Term of Swallowing and Quality of Life After Prophylactic Versus Reactive Percutaneous Endoscopic Gastrostomy Tube Placement in Advanced Oropharyngeal Cancer Patients Treated With Definitive Chemo-radiotherapy Recruiting NCT04019548 Phase 3 Cisplatin injection
20 A Phase III Randomized Trial of Post-operative Adjuvant Nivolumab and Concomitant Chemo-radiotherapy in High-risk Patients With Resected Squamous Cell Carcinoma of Head and Neck Recruiting NCT03576417 Phase 3 Cisplatin;Nivolumab
21 A Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients With Early-Stage, P16-Positive, Non-Smoking Associated Oropharyngeal Cancer Recruiting NCT03952585 Phase 2, Phase 3 Cisplatin
22 A Phase II/III Trial of Risk-stratified, Reduced Intensity Adjuvant Treatment in Patients Undergoing Transoral Surgery for Human Papillomavirus (HPV)-Positive Oropharyngeal Cancer Recruiting NCT02215265 Phase 3 Cisplatin
23 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Recruiting NCT03258554 Phase 2, Phase 3
24 Phase II/III Randomized Trial of Intensity-Modulated Proton Beam Therapy (IMPT) Versus Intensity-Modulated Photon Therapy (IMRT) for the Treatment of Oropharyngeal Cancer of the Head and Neck Recruiting NCT01893307 Phase 2, Phase 3
25 Definitive Chemo-Radiotherapy With or Without Up-front Neck Dissection for Regionally Advanced Head and Neck Squamous Cell Carcinoma: A Phase III Multi-center Prospective Randomized Controlled Trial With Two Additional Observational Cohorts Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
26 Phase III Trial of Radiotherapy Plus Cetuximab Versus Chemoradiotherapy in HPV-Associated Oropharynx Cancer Active, not recruiting NCT01302834 Phase 3 cisplatin
27 Phase III Trial Testing the Benefit of Intensity-modulated Radiotherapy With Weekly Replanifications Versus Intensity Modulated Radiotherapy With Only One Planification in Locally Advanced Oropharynx Carcinoma for Decreasing Xerostomia Active, not recruiting NCT01874587 Phase 3
28 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
29 The Quarterback Trial: A Randomized Phase III Clinical Trial Comparing Reduced and Standard Radiation Therapy Doses for Locally Advanced HPV Positive Oropharynx Cancer Active, not recruiting NCT01706939 Phase 3 Carboplatin
30 A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination With Tremelimumab Versus Standard of Care Therapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Active, not recruiting NCT02369874 Phase 3 MEDI4736;MEDI4736 + Tremelimumab;Standard of Care
31 Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia Active, not recruiting NCT01266044 Phase 3
32 A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer Active, not recruiting NCT00956007 Phase 3
33 Randomized Phase III Trial to Compare Radiation Therapy Alone With Radiation Therapy and Concomitant Anti-EGFr Antibody (C225) for Locally Advanced Squamous Cell Carcinomas of the Head and Neck Terminated NCT00004227 Phase 3
34 A Phase III Trial of Standard Fractionation Radiation and Concurrent Single Agent Cisplatin, With and Without Docetaxel, Cisplatin, and 5-Fluorouracil Induction Chemotherapy, in Patients With Advanced Oropharyngeal Squamous Cell Cancer Terminated NCT00268372 Phase 3 cisplatin;docetaxel;5-fluorouracil
35 Adjuvant De-escalation, Extracapsular Spread, P16+, Transoral (ADEPT) Trial for Oropharynx Malignancy Terminated NCT01687413 Phase 3 Cisplatin
36 Randomized Evaluation of a Phytopharmaceutical in Prevention of Severe Oral Mucositis in Patients Receiving Radiotherapy for Oral Cavity, Oropharynx, Hypopharynx, or Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
37 Randomized Phase III Trial on Postoperative Chemoradiation in Combination With Anti EGFR-Antibody Versus Postoperative Chemoradiation in Head and Neck Squamous Cell Carcinomas (HNSCC) With High Risk of Locoregional Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
38 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
39 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Unknown status NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
40 A Pilot Study of Combined Modality Therapy for Recurrent Head and Neck Carcinoma Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
41 A Phase II Trial of Paclitaxel (TAXOL) Administered as a Weekly One Hour Infusion in Previously Treated Patients With Advanced Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
42 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
43 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
44 Neoadjuvant and Concurrent Chemoradiotherapy Plus Nimotuzumab in Treating Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Oropharynx and Hypopharynx Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
45 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
46 A Single-arm Phase II Study of Post-Transoral Robotic Surgery (TORS) Alone to the Primary Tumor Site and Selective Neck Dissection (SND) Followed by Adjuvant Radiation Therapy (+/- Chemotherapy) to the Regional Nodes for Advanced Stage, Human Papilloma Virus (HPV) Positive, Oropharyngeal Cancer Completed NCT02159703 Phase 2
47 Conformal and Intensity Modulated Irradiation for Oropharyngeal Cancer Completed NCT00006360 Phase 1, Phase 2 radioprotection
48 Pilot Study for the Diagnosis of Head and Neck Cancer: Photofrin and Visible Light Completed NCT00002964 Phase 2 porfimer sodium
49 Respiratory-Swallow Training in Veterans With Oropharyngeal Cancer Completed NCT01032928 Phase 2
50 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2

Search NIH Clinical Center for Oropharynx Cancer

Genetic Tests for Oropharynx Cancer

Anatomical Context for Oropharynx Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Oropharynx Cancer:

19
The

MalaCards organs/tissues related to Oropharynx Cancer:

40
Tongue, Lymph Node, Testes, Tonsil, T Cells, Lung, Breast

Publications for Oropharynx Cancer

Articles related to Oropharynx Cancer:

(show top 50) (show all 2705)
# Title Authors PMID Year
1
A possible role of thymidine phosphorylase expression and 5-fluorouracil increased sensitivity in oropharyngeal cancer patients. 61 54
17378915 2007
2
Laryngeal and oropharyngeal cancer, and alcohol dehydrogenase 3 and glutathione S-transferase M1 polymorphisms. 61 54
9050916 1997
3
Methylation of HPV 16 and EPB41L3 in oral gargles: Associations with oropharyngeal cancer detection and tumor characteristics. 61
31304592 2020
4
New perspective on SH2B1: An accelerator of cancer progression. 61
31739166 2020
5
Stage I HPV-positive oropharyngeal cancer: Should all patients receive similar treatments? 61
31536144 2020
6
Do not de-escalate oncology care in oropharyngeal cancer routinely. 61
31512784 2020
7
Predictors of swallow function after transoral surgery for locally advanced oropharyngeal cancer. 61
30957243 2020
8
Mortality due to oral and oropharyngeal cancer in Uruguay from 1997 to 2014. 61
31800875 2020
9
Return to Work in Survivors of Human Papillomavirus-Associated Oropharyngeal Cancer: An Australian Experience. 61
31521718 2020
10
Effects of oral and oropharyngeal cancer on speech intelligibility using acoustic analysis: Systematic review. 61
31571334 2020
11
Reply to "Do not de-escalate oncology care in oropharyngeal cancer routinely". 61
31512788 2020
12
Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. 61
31037378 2020
13
Patient-reported receipt of oral cancer screenings and smoking cessation counseling from US oral health care providers: National Health and Nutrition Examination Survey, 2015-2016. 61
31761028 2019
14
Development and validation of an individualized risk prediction model for oropharynx cancer in the US population. 61
31454434 2019
15
In-Office Injection Pharyngoplasty for Velopharyngeal Insufficiency After Oropharyngeal Cancer Treatment. 61
30730561 2019
16
[Subcutaneous foreign body granuloma after neck dissection and adjuvant radiation]. 61
31187149 2019
17
Phase IIb, Randomized, Double-Blind Trial of GC4419 Versus Placebo to Reduce Severe Oral Mucositis Due to Concurrent Radiotherapy and Cisplatin For Head and Neck Cancer. 61
31618127 2019
18
Nail squamous cell carcinoma: A hidden high-risk human papillomavirus reservoir for sexually transmitted infections. 61
30930083 2019
19
Acoustofluidic Salivary Exosome Isolation: A Liquid Biopsy Compatible Approach for Human Papillomavirus-Associated Oropharyngeal Cancer Detection. 61
31843276 2019
20
Risk of subsequent malignant neoplasms after an index potentially-human papillomavirus (HPV)-associated cancers. 61
31816512 2019
21
Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma. 61
31845736 2019
22
National treatment trends in human papillomavirus-positive oropharyngeal squamous cell carcinoma. 61
31825543 2019
23
Milk and dairy products consumption and the risk of oral or oropharyngeal cancer: a meta-analysis. 61
31789344 2019
24
CASP8 (rs3834129) and CASP3 (rs4647601) polymorphisms in oropharynx cancer risk, tumor cell differentiation, and prognosis in a cohort of the Brazilian population. 61
31587185 2019
25
Lessons Learned from Deescalation Trials in Favorable Risk HPV-Associated Squamous Cell Head and Neck Cancer-A Perspective on Future Trial Designs. 61
31527164 2019
26
Impact of contralateral lymph nodal involvement and extranodal extension on survival of surgically managed HPV-positive oropharyngeal cancer staged with the AJCC eighth edition. 61
31630059 2019
27
A genetic variant within MDM4 3'UTR miRNA binding site is associated with HPV16-positive tumors and survival of oropharyngeal cancer. 61
31513313 2019
28
Optimising Radiation Therapy Dose to the Swallowing Organs at Risk: An In Silico Study of feasibility for Patients with Oropharyngeal Tumours. 61
30741335 2019
29
Quantitative oral HPV16 and HPV18 detection in persons attending dental clinics. 61
31804297 2019
30
Dental professionals' knowledge, attitudes, and practice behaviors related to human papillomavirus vaccination. 61
31788802 2019
31
Evaluation of the cancer stem cell marker DCLK1 in patients with lymph node metastases of head and neck cancer. 61
31706685 2019
32
Knowledge-based automated planning with three-dimensional generative adversarial networks. 61
31675444 2019
33
Anatomical subsite modifies survival in oropharyngeal squamous cell carcinoma: National Cancer Database study. 61
31773842 2019
34
Improving exposure for transoral oropharyngeal surgery with the floor of mouth window: a cadaveric feasibility study. 61
31718714 2019
35
Detection and quantitation of human papillomavirus DNA in peripheral blood mononuclear cells from blood donors. 61
31317547 2019
36
Solitary cystic metastatic lymph node of occult human papillomavirus-related oropharyngeal cancer mimicking second branchial cleft cyst: A case report. 61
31689859 2019
37
Significance of Anthropometric and Nutritive Factors in Oral and Oropharyngeal Cancer Patients Undergoing Free Flap Reconstruction. 61
31838094 2019
38
Second primary anal and oropharyngeal cancers in cervical cancer survivors. 61
31128108 2019
39
Swallowing-related outcomes associated with late lower cranial neuropathy in long-term oropharyngeal cancer survivors: cross-sectional survey analysis. 61
31441572 2019
40
Pathologic response to neoadjuvant chemotherapy in HPV-associated oropharynx cancer. 61
31773857 2019
41
HPV-associated oropharyngeal cancer: Erratum. 61
31663903 2019
42
Impact of active smoking on outcomes in HPV+ oropharyngeal cancer. 61
31769100 2019
43
Pruritic bullous skin eruption in a male patient receiving immunotherapy for oropharyngeal cancer. 61
31782147 2019
44
The Role of the Dental Community in Oropharyngeal Cancer Prevention Through HPV Vaccine Advocacy. 61
31728921 2019
45
Bilateral vertebral collections in a patient with "end-stage" osteoradionecrosis after radiotherapy for oropharyngeal cancer. 61
31767134 2019
46
Factors associated with employment discontinuation among older and working age survivors of oropharyngeal cancer. 61
31490588 2019
47
Effects of jaw exercise intervention timing on outcomes following oral and oropharyngeal cancer surgery: Pilot study. 61
31407421 2019
48
Trimodality therapy for HPV-positive oropharyngeal cancer: A population-based study: Trimodality therapy for HPV+ OPC. 61
31536843 2019
49
Functional role of miR-148a in oropharyngeal cancer: influence on pregnane X receptor and P-glycoprotein expression. 61
31771390 2019
50
Head and Neck Cancer Risk Prediction Models for the US Population from the INHANCE Consortium. 61
31781743 2019

Variations for Oropharynx Cancer

Cosmic variations for Oropharynx Cancer:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM90409508 upper aerodigestive tract,oropharynx,carcinoma,squamous cell carcinoma c.3734G>A p.R1245Q 16:2081718-2081718 0

Expression for Oropharynx Cancer

Search GEO for disease gene expression data for Oropharynx Cancer.

Pathways for Oropharynx Cancer

Pathways related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.82 TP53 MAML2 KIT ERBB2 EGFR APC
2
Show member pathways
12.7 TP53 KIT ERBB2 EGFR CDKN2A APC
3 12.66 TP53 KIT ERBB2 EGFR CDKN2A APC
4
Show member pathways
12.47 TP53 KIT ERBB2 EGFR CDKN2A APC
5
Show member pathways
12.24 TYMP KIT ERBB2 EGFR APC
6 11.79 TP53 ERBB2 CDKN2A APC
7 11.71 TP53 EGFR CDKN2A APC
8 11.66 TP53 MIR9-1 MIR193B ERBB2 EGFR CDKN2A
9 11.58 TP53 ERBB2 CDKN2A
10 11.53 ERBB2 EGFR APC
11 11.4 TP53 KIT ERBB2 EGFR
12 11.38 TP53 EGFR CDKN2A
13 11.28 TP53 NFIB MYBL1 ERBB2
14 11.22 TYMP TP53 ERBB2 EGFR CDKN2A
15 11.06 ERBB2 EGFR APC

GO Terms for Oropharynx Cancer

Biological processes related to Oropharynx Cancer according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 9.8 TP53 NFIB MYBL1 MAML2 EGFR CRTC1
2 positive regulation of gene expression GO:0010628 9.77 TP53 MMP8 KIT ERBB2 CDKN2A
3 negative regulation of cell proliferation GO:0008285 9.72 TP53 NFIB MIR9-1 CDKN2A APC
4 replicative senescence GO:0090399 9.51 TP53 CDKN2A
5 positive regulation of pseudopodium assembly GO:0031274 9.49 KIT APC
6 tongue development GO:0043586 9.48 KIT EGFR
7 regulation of microtubule-based process GO:0032886 9.46 ERBB2 APC
8 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.43 TP53 EGFR
9 somatic stem cell division GO:0048103 9.4 KIT CDKN2A
10 positive regulation of MAP kinase activity GO:0043406 9.33 KIT ERBB2 EGFR
11 negative regulation of ERBB signaling pathway GO:1901185 8.96 ERBB2 EGFR
12 negative regulation of immature T cell proliferation in thymus GO:0033088 8.62 ERBB2 CDKN2A

Molecular functions related to Oropharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein phosphatase binding GO:0019903 9.13 TP53 ERBB2 EGFR
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 KIT ERBB2 EGFR

Sources for Oropharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....